iCAD (NASDAQ:ICAD) Share Price Passes Above 200-Day Moving Average – Here’s What Happened

iCAD, Inc. (NASDAQ:ICAD)’s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.50 and traded as high as $2.05. iCAD shares last traded at $1.93, with a volume of 208,366 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com upgraded iCAD from a “sell” rating to a “hold” rating in a research report on Thursday, August 22nd.

iCAD Stock Performance

The stock has a market cap of $51.22 million, a PE ratio of -16.08 and a beta of 1.50. The business has a 50-day moving average of $1.61 and a 200 day moving average of $1.50.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings data on Tuesday, August 13th. The technology company reported ($0.07) EPS for the quarter. The company had revenue of $5.03 million for the quarter. iCAD had a negative return on equity of 13.59% and a negative net margin of 15.67%.

Institutional Trading of iCAD

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICAD. AMH Equity Ltd purchased a new stake in iCAD in the 1st quarter valued at about $207,000. First Eagle Investment Management LLC grew its holdings in iCAD by 3.2% in the 1st quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock valued at $1,129,000 after buying an additional 22,000 shares during the period. Perritt Capital Management Inc. grew its holdings in iCAD by 7.5% in the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after buying an additional 9,717 shares during the period. Virtu Financial LLC grew its holdings in iCAD by 55.6% in the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after buying an additional 7,604 shares during the period. Finally, Perritt Capital Management Inc grew its holdings in iCAD by 14.2% in the 2nd quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after buying an additional 19,917 shares during the period. Hedge funds and other institutional investors own 24.61% of the company’s stock.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.